US Patent

US10626088 — Determining degradation of 3,4-diaminopyridine

Formulation · Assigned to Jacobus Pharmaceutical Co Inc · Expires 2037-02-25 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for determining the purity and detecting degradation of 3,4-diaminopyridine, a compound that includes amifampridine phosphate.

USPTO Abstract

The present invention relates to methods of determining the purity of a sample of 3,4-diaminopyridine comprising determining the presence, absence, or amount of a dimer of 3,4-diaminopyridine or a dimer of 3,4-diaminopyridine in the form of a salt, solvate or complex or a combination thereof. The invention also relates to methods of detecting and quantitating degradation in a sample of 3,4-diaminopyridine. Dimers of 3,4-diaminopyridine and methods of making and isolating the same are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US10626088
Jurisdiction
US
Classification
Formulation
Expires
2037-02-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Jacobus Pharmaceutical Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.